Price (delayed)
$0.151
Market cap
$10.23M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.07
Enterprise value
-$31.83M
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has
There are no recent dividends present for APTX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.